\setlength{\LTpost}{0mm}
\begin{longtable}{llrrrrr}
\toprule
\multicolumn{2}{c}{ATC sub-group} & \multicolumn{2}{c}{\# of users} & \multicolumn{3}{c}{Cox hazard risk (HR) estimates} \\ 
\cmidrule(lr){1-2} \cmidrule(lr){3-4} \cmidrule(lr){5-7}
symbol & description & non-PD users & PD users & HR & 95\% CI & FDR p-value\textsuperscript{1} \\ 
\midrule
\multicolumn{7}{l}{drugs decreasing PD risk} \\ 
\midrule
R03 & Drugs For Obstructive Airway Diseases & $646,098$ & $2,353$ & $0.86$ & $0.82$–$0.90$ & $8.97 \times 10^{-10}$ \\ 
N07 & Other Nervous System Drugs & $148,201$ & $246$ & $0.68$ & $0.60$–$0.77$ & $4.11 \times 10^{-8}$ \\ 
H02 & Corticosteroids For Systemic Use & $602,296$ & $1,883$ & $0.88$ & $0.84$–$0.93$ & $1.44 \times 10^{-5}$ \\ 
C09 & Agents Acting On The Renin-Angiotensin System & $964,289$ & $5,675$ & $0.92$ & $0.89$–$0.95$ & $2.38 \times 10^{-5}$ \\ 
S03 & Ophthalmological And Otological Preparations & $175,782$ & $584$ & $0.83$ & $0.77$–$0.91$ & $3.10 \times 10^{-4}$ \\ 
P01 & Antiprotozoals & $221,462$ & $548$ & $0.85$ & $0.78$–$0.93$ & $3.88 \times 10^{-3}$ \\ 
J01 & Antibacterials For Systemic Use & $2,339,776$ & $8,987$ & $0.95$ & $0.92$–$0.98$ & $2.12 \times 10^{-2}$ \\ 
L01 & Antineoplastic Agents & $45,618$ & $75$ & $0.69$ & $0.55$–$0.87$ & $2.29 \times 10^{-2}$ \\ 
J07 & Vaccines & $223,683$ & $661$ & $0.89$ & $0.82$–$0.96$ & $4.90 \times 10^{-2}$ \\ 
R05 & Cough And Cold Preparations & $1,088,879$ & $3,980$ & $0.95$ & $0.91$–$0.98$ & $4.90 \times 10^{-2}$ \\ 
\midrule
\multicolumn{7}{l}{drugs increasing PD risk} \\ 
\midrule
N06 & Psychoanaleptics & $718,141$ & $4,184$ & $1.94$ & $1.87$–$2.01$ & $1.40 \times 10^{-284}$ \\ 
G04 & Urologicals & $501,181$ & $4,016$ & $1.48$ & $1.42$–$1.53$ & $4.90 \times 10^{-86}$ \\ 
N05 & Psycholeptics & $1,215,580$ & $6,603$ & $1.40$ & $1.35$–$1.44$ & $4.90 \times 10^{-86}$ \\ 
N03 & Antiepileptics & $272,316$ & $1,232$ & $1.48$ & $1.40$–$1.57$ & $4.11 \times 10^{-38}$ \\ 
A06 & Drugs For Constipation & $193,897$ & $748$ & $1.60$ & $1.49$–$1.73$ & $8.22 \times 10^{-34}$ \\ 
C07 & Beta Blocking Agents & $737,783$ & $5,411$ & $1.21$ & $1.17$–$1.26$ & $6.04 \times 10^{-27}$ \\ 
B01 & Antithrombotic Agents & $991,945$ & $7,080$ & $1.17$ & $1.13$–$1.21$ & $5.50 \times 10^{-18}$ \\ 
A11 & Vitamins & $404,520$ & $1,552$ & $1.24$ & $1.18$–$1.31$ & $4.21 \times 10^{-14}$ \\ 
S01 & Ophthalmologicals & $1,317,128$ & $5,873$ & $1.14$ & $1.10$–$1.17$ & $3.33 \times 10^{-12}$ \\ 
N02 & Analgesics & $1,863,651$ & $7,182$ & $1.12$ & $1.09$–$1.16$ & $8.96 \times 10^{-11}$ \\ 
M05 & Drugs For Treatment Of Bone Diseases & $166,809$ & $1,047$ & $1.26$ & $1.18$–$1.34$ & $2.74 \times 10^{-10}$ \\ 
C01 & Cardiac Therapy & $318,119$ & $2,225$ & $1.17$ & $1.12$–$1.23$ & $2.87 \times 10^{-10}$ \\ 
B03 & Antianemic Preparations & $420,616$ & $1,792$ & $1.17$ & $1.11$–$1.23$ & $2.13 \times 10^{-8}$ \\ 
D01 & Antifungals For Dermatological Use & $393,728$ & $1,644$ & $1.17$ & $1.12$–$1.24$ & $2.13 \times 10^{-8}$ \\ 
A12 & Mineral Supplements & $370,972$ & $1,620$ & $1.17$ & $1.11$–$1.24$ & $6.23 \times 10^{-8}$ \\ 
H01 & Pituitary And Hypothalamic Hormones And Analogues & $43,766$ & $102$ & $1.77$ & $1.45$–$2.15$ & $2.79 \times 10^{-7}$ \\ 
A03 & Drugs For Functional Gastrointestinal Disorders & $210,974$ & $633$ & $1.24$ & $1.14$–$1.34$ & $3.53 \times 10^{-6}$ \\ 
A02 & Drugs For Acid Related Disorders & $892,450$ & $3,796$ & $1.10$ & $1.06$–$1.14$ & $2.38 \times 10^{-5}$ \\ 
M01 & Antiinflammatory And Antirheumatic Products & $2,015,797$ & $8,179$ & $1.07$ & $1.03$–$1.10$ & $1.13 \times 10^{-3}$ \\ 
G03 & Sex Hormones And Modulators Of The Genital System & $748,809$ & $2,190$ & $1.10$ & $1.04$–$1.15$ & $5.49 \times 10^{-3}$ \\ 
A01 & Stomatological Preparations & $70,916$ & $243$ & $1.23$ & $1.09$–$1.40$ & $1.75 \times 10^{-2}$ \\ 
\bottomrule
\end{longtable}
\begin{minipage}{\linewidth}
\textsuperscript{1}p-value adjusted for false discovery rate\\
\end{minipage}

